Milner Therapeutics Institute to Feature at BioTrinity 2026

The Milner Therapeutics Institute is set to play a pivotal role at BioTrinity 2026. With an engaging showcase session and participation in a critical panel discussion, the Institute aims to highlight the power of collaboration within the life sciences industry. As this event marks the 20th edition of OBN’s two-day conference, it promises to be a significant catalyst for growth in the sector.

On April 14th, the Milner Institute will lead the “Milner Incubator Showcase” featuring groundbreaking science and innovative partnerships from its incubator companies. This session will provide insight into how collaborations among academia, industry, and entrepreneurs spur innovation and transform research into impactful solutions. Concurrently, Cathy Tralau-Stewart, the Executive Director of Milner, will contribute to a panel on “Unlocking the Power of Collaboration.” Discussions will focus on leveraging partnerships as a core strategy for R&D-focused SMEs, involving academia, industry, investors, and the NHS. This setting underscores the importance of cooperation in accelerating development and extending capabilities within the life sciences.

BioTrinity 2026 is a landmark event for life sciences, and the Milner Institute’s involvement underscores its commitment to fostering collaboration and innovation. This participation not only signifies a step forward for the Institute but also highlights emerging trends that could redefine the industry landscape. We eagerly anticipate the transformative ideas that will emerge from this gathering and hope to see you there!